Given the success of Research Topic
Manipulation of Gut Microbiota as a Key Target to Intervene on the Onset and Progression of Digestive System Diseases and the rapidly evolving subject area, we are pleased to announce the launch of Volume II.
Recently, the gut microbiota has been widely acknowledged to exert a crucial role in the onset and progression of digestive system diseases, including inflammatory bowel disease (IBD), colorectal cancer (CRC), and other gastrointestinal diseases, as well as non-alcoholic fatty liver disease (NAFLD) and liver cirrhosis. Manipulation of the gut microbiota through dietary modifications, antibiotics, probiotics, fecal microbiota transplantation (FMT), and other methods represents a promising therapeutic avenue in patients with digestive system diseases. However, the interaction between gut microbiota and enterohepatic diseases remains not fully revealed. Besides, the specific effects and underlying mechanisms of microbial manipulation for disease prevention and treatment need to be further explored.
This Research Topic aims at discussing whether and how gut microbial intervention with different methods could become an indispensable part of the prevention and treatment of digestive system diseases. We would like to declare causal relationships between the gut microbiota and digestive system diseases, as well as identify the core microbiota that is involved in the onset and progression of enterohepatic diseases. We would also like to update recent advances in novel gut microbiota manipulation tools for enterohepatic diseases, such as live bio-therapeutics and new FMT. Our topic is expected to partly elucidate the mechanisms underlying the gut microbiota role in digestive system diseases through host immunity, metabolism, inflammation, and other multifaceted perspectives.
We welcome submissions of Original Research, Reviews, Clinical Trials, and Commentaries which cover, but are not limited to, the following topics:
• Application of novel microbiota manipulation tools in the prevention and treatment of digestive system diseases.
• Description of the specific microbiota taxa involved in the onset and progression of digestive system diseases.
• Exploration of the interaction between gut microbiota and digestive system diseases.
• Evaluation of clinical models or microbial biomarkers to predict the outcome of digestive system diseases.
